Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
-
ABL1 p.Thr334Ile (p.T334I)
(
ENST00000372348.9,
ENST00000318560.6 )
ABL1 p.Thr334Ile (p.T334I) ( ENST00000372348.9, ENST00000318560.6 ) - Associated Disease
- refractory CML
- Source Database
- DisGeNET
- Description
- The leading third-generation clinical candidate for treatment-refractory CML, including patients with the T315I mutation, is ponatinib (AP24534), a pan-BCR-ABL inhibitor that has entered pivotal phase 2 testing.
- Pubmed
- 21098337
- Original source reporting the Gene Disease association
- BeFree
- DisGENET score for the Gene Disease association
- 0.00081432561624091
- Year of publication
- 2011
Drugs